Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome
- PMID: 33009062
- DOI: 10.14309/ajg.0000000000000946
Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome
Abstract
Introduction: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder, which follows a relapsing and remitting course. Little is known about how evolving definitions of IBS or treatment for the condition affect symptom stability. We conducted a 12-month longitudinal follow-up study of individuals who self-identified as having IBS to examine these issues.
Methods: We collected demographic, gastrointestinal symptom, mood, and psychological health data at baseline, and gastrointestinal symptom data at 12 months, from adults who self-identified as having IBS, registered with 3 organizations providing services to people with IBS. We applied the Rome III and Rome IV criteria simultaneously at baseline and 12 months and subtyped participants according to predominant stool form or frequency. We examined stability of a diagnosis of IBS, and stability of IBS subtype, for the Rome IV and III criteria separately and examined the effect of commencing new therapy on fluctuation of symptoms.
Results: Of 1,375 individuals recruited at baseline, 784 (57.0%) provided data at 12 months. Of these, 452 met the Rome IV criteria for IBS at baseline, of whom 133 (29.4%) fluctuated to another functional bowel disorder at 12 months. In the remaining 319 (70.6%) who still met the Rome IV criteria for IBS, IBS subtype changed in 101 (31.7%) subjects, with IBS with mixed bowel habit (IBS-M) the least stable. Commencing a new treatment for IBS did not affect symptom stability. Among 631 who met the Rome III criteria at baseline responding at 12 months, 104 (16.5%) fluctuated to another functional bowel disorder. In the 527 (83.5%) who still met the Rome III criteria for IBS, IBS subtype fluctuated in 129 (24.5%), with IBS-M the most stable subtype. Again, commencing a new treatment for IBS did not affect symptom stability.
Discussion: Fluctuation between functional bowel disorders and predominant stool subtype is common in people with IBS and does not appear to be influenced solely by treatment. Rome IV IBS appears less stable than Rome III IBS.
Copyright © 2020 by The American College of Gastroenterology.
Similar articles
-
A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles.Am J Gastroenterol. 2021 Feb 1;116(2):372-381. doi: 10.14309/ajg.0000000000000975. Am J Gastroenterol. 2021. PMID: 33110014
-
Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria.Clin Gastroenterol Hepatol. 2020 Feb;18(2):392-398.e2. doi: 10.1016/j.cgh.2019.05.037. Epub 2019 May 31. Clin Gastroenterol Hepatol. 2020. PMID: 31154027
-
Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern.Neurogastroenterol Motil. 2014 Jan;26(1):36-45. doi: 10.1111/nmo.12220. Epub 2013 Aug 29. Neurogastroenterol Motil. 2014. PMID: 23991913 Free PMC article.
-
Irritable Bowel Syndrome: Straightening the road from the Rome criteria.Neurogastroenterol Motil. 2020 Nov;32(11):e13957. doi: 10.1111/nmo.13957. Epub 2020 Aug 17. Neurogastroenterol Motil. 2020. PMID: 32808411 Free PMC article. Review.
-
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. Lancet Gastroenterol Hepatol. 2020. PMID: 32702295
Cited by
-
New paradigm of oral rehydration in patients affected by irritable bowel syndrome with chronic diarrhea.World J Gastrointest Pharmacol Ther. 2024 Mar 20;15(1):90933. doi: 10.4292/wjgpt.v15.i1.90933. World J Gastrointest Pharmacol Ther. 2024. PMID: 38590832 Free PMC article.
-
Does sourdough bread provide clinically relevant health benefits?Front Nutr. 2023 Jul 20;10:1230043. doi: 10.3389/fnut.2023.1230043. eCollection 2023. Front Nutr. 2023. PMID: 37545587 Free PMC article. Review.
-
Diagnostic strategy of irritable bowel syndrome: a low- and middle-income country perspective.Intest Res. 2024 Jul;22(3):286-296. doi: 10.5217/ir.2023.00199. Epub 2024 Mar 26. Intest Res. 2024. PMID: 38528371 Free PMC article. Review.
-
Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities.Neurogastroenterol Motil. 2022 Nov;34(11):e14391. doi: 10.1111/nmo.14391. Epub 2022 May 9. Neurogastroenterol Motil. 2022. PMID: 35531932 Free PMC article.
-
Acupuncture and related therapies for the anxiety and depression in irritable bowel syndrome with diarrhea (IBS-D): A network meta-analysis of randomized controlled trials.Front Psychiatry. 2022 Dec 23;13:1067329. doi: 10.3389/fpsyt.2022.1067329. eCollection 2022. Front Psychiatry. 2022. PMID: 36620677 Free PMC article.
References
-
- Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480–91.
-
- Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393–407.
-
- Drossman DA, Thompson WG, Talley NJ. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Intl 1990;3:159–72.
-
- Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 2020. (doi: 10.1053/j.gastro.2020.04.014 ). - DOI
-
- Black CJ, Yiannakou Y, Houghton LA, et al. Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clin Gastroenterol Hepatol 2020;18:392–8.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous